Team discovers opportunities to overcome cancer treatment resistance

April 27, 2017, Cleveland Clinic
cancer
Killer T cells surround a cancer cell. Credit: NIH

A collaborative Cleveland Clinic, University of Oxford and Moffitt Cancer Center team of researchers has proven the theory that, while resistance to targeted treatment in cancer is truly a moving target, there are opportunities to overcome the resistance that develops. Though more study is needed, researchers believe understanding and predicting tumor resistance may translate into additional treatment options in the clinical setting.

Treatment resistance that develops as cancer cells evolve is one of the major limitations of targeted cancer therapies today. During this progression, cancer cells not only change their response to the being used to treat the cancer, but also to many other drugs. In some cases, they become susceptible to another drug, called collateral sensitivity. In other cases, two drugs are simultaneously resisted, referred to as cross-resistance.

The research team led by Jacob Scott, M.D., a physician-scientist in the department of Translational Hematology and Oncology Research and Radiation Oncology at Cleveland Clinic, studied non-small cell lung cancer (NSCLC) cells and found that the drug resistance that developed did not apply to every drug, and were even sometimes more susceptible towards other drugs. These patterns of resistance and susceptibility changed over time. Understanding this, and how to measure these changes, the team ascertains that it may be possible to design and predict new options and schedules.

"While the discovery of drugs that target molecular pathways responsible for has been a paradigm shift in the way we treat many cancers, often the drugs inevitably fail," said Dr. Scott. "The end goal of our research is to understand, and predict, the changes tumors experience during treatment so we can better plan second-line therapy when the unavoidable drug failures occur."

In the study, researchers performed a series of evolution experiments, creating resistance to a number of drugs used to treat a specific NSCLC. They tested these evolved cells against a large family of other drugs to better understand the changes they experienced. The impact of "drug holidays," or treatment interruptions, was also examined. This research is among the first to report on drug holidays and cross resistance together, and discovered that drug holidays impact primary drug resistance and susceptibility in a profound way.

"Researchers have known that avoiding cross- is key; this investigation tells us we also need to start considering drug holidays as well," said Dr. Scott. "We hope our work informs future similar studies across a variety of types, and eventually results in more tailored treatment plans for patients."

The study is published in Scientific Reports.

Explore further: Acquired resistance to combination drug treatment in cancer

More information: Scientific Reports, www.nature.com/articles/s41598-017-00791-8

Related Stories

Acquired resistance to combination drug treatment in cancer

September 5, 2016
A team of scientists led by Dr Bhaskar Bhattacharya and Associate Professor Richie Soong from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) conducted a study on acquired ...

Drug resistance biomarker could improve cancer treatment

November 21, 2012
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published ...

New drug combination shows promise in tackling leukaemia treatment resistance

October 17, 2016
Early testing of a new drug combination that attacks the most common form of leukaemia on multiple fronts has shown great promise in targeting cancer cells.

Study identifies how cancer cells may develop resistance to FGFR inhibitors

March 2, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a mechanism by which cancer cells ...

Targeting low-oxygen patches inside lung cancer tumors could help prevent drug resistance

August 25, 2016
With the right treatment schedule, medications known as hypoxia-activated prodrugs (HAPs) could help prevent drug resistance in a subtype of lung cancer, according to a study published in PLOS Computational Biology.

HIV drug could stop skin cancer becoming drug-resistant

March 14, 2016
An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell today.

Recommended for you

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

New treatment helps avoid deafness in child chemotherapy patients

June 21, 2018
An international trial has found that a medicine commonly used to treat poisoning is effective in reducing deafness in children receiving chemotherapy for cancer.

New therapeutic opportunity for the treatment of resistant malignant melanoma

June 21, 2018
A team of researchers led by Dr. Pierre Close, WELBIO researcher at the ULiège GIGA Institute and Dr. Francesca Rapino has uncovered a new therapeutic opportunity in the treatment of malignant melanoma that has acquired ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.